Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $3.61B | +19.0% | $727.2M | $6.75 | -7.2% | 81.4% | 20.7% |
| Q4 2025 Dec 2025 | $3.88B | — | $844.6M | $7.86 | — | 85.0% | 23.1% |
| Q3 2025 Sep 2025 | $3.75B | — | $1.46B | $13.62 | — | 86.1% | 29.6% |
| Q2 2025 Jun 2025 | $3.68B | — | $1.39B | $12.81 | — | 85.6% | 29.4% |
| Q1 2025 Mar 2025 | $3.03B | — | $808.7M | $7.27 | — | 84.7% | 19.5% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Can the Regeneron Melanoma Trial setback derail the biotech’s oncology growth story, or will upcoming data flip the narrative? Maik Kemper Editor in Chief Conclusion Against a backdrop…